ReviewMayo Clinic proceedings2010
Cancer-associated myeloproliferation: old association, new therapeutic target.
Review in Mayo Clinic proceedings, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- Leukemoid Reactions in Pancreatic Cancer: A Case Series.The American journal of case reports · 2025Article
- Article
- Primary hepatic squamous cell carcinoma: case report and systematic review of the literature.Frontiers in oncology · 2023Article
- Be(a)ware of Leukocytosis in Papillary Thyroid Cancer.Case reports in endocrinology · 2022Article
- Nomograms to predict the prognosis in locally advanced oral squamous cell carcinoma after curative resection.BMC cancer · 2021Article
- Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review.World journal of gastrointestinal oncology · 2021Review
- Paraneoplastic leukemoid reaction in a localised squamous cell oesophageal cancer with paracrine G-CSF production.BMJ case reports · 2020Article
- Paraneoplastic leukemoid reactions induced by cytokine-secreting tumours.Journal of clinical pathology · 2020Review
- Comparison of Artificial Neural Networks and Logistic Regression for 30-days Survival Prediction of Cancer Patients.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2020Article
- The Generation and Identity of Human Myeloid-Derived Suppressor Cells.Frontiers in oncology · 2020Review
- CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3.Cell death & disease · 2019Article
- Clinicopathologic characteristics and survival analysis in stage IVB cervical cancer with hematogenous metastasis.Translational cancer research · 2019Article
- Longitudinal investigation of haematological alterations among permethrin-exposed pesticide applicators in the Biomarkers of Exposure and Effect in Agriculture study.Occupational and environmental medicine · 2019Article
- Paraneoplastic leukemoid reaction in a patient with sarcomatoid hepatocellular carcinoma: A case report.World journal of clinical cases · 2019Article
- Blood immune cell biomarkers in lung cancer.Clinical and experimental immunology · 2019Article
- Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity.Frontiers in immunology · 2019Review
- Syphilis infection in an HIV patient presenting with leukemoid reaction: Case report and review of the literature.Infectious disease reports · 2018Article
- Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy.Research and reports in urology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between malignancy and development of a paraneoplastic leukocytosis, the so-called leukemoid reaction, has long been appreciated. Although a leukemoid reaction has conventionally been defined as a peripheral blood leukocytosis composed of both mature and immature granulocytes that exceeds 50,000/microL, a less profound leukocytosis may be appreciated in many patients harboring a malignant disease. More recent insights have shed new light on this long-recognized association, because research performed in both murine models and cancer patients has uncovered multiple mechanisms by which tumors both drive myelopoiesis, sometimes leading to a clinically apparent leukocytosis, and inhibit the differentiation of myeloid cells, resulting in a qualitative change in myelopoiesis. This qualitative change leads to the accumulation of immature myeloid cells, which due to their immune suppressive effects have been collectively called myeloid-derived suppressor cells. More recently, myeloid cells have been shown to promote tumor angiogenesis. Cancer-associated myeloproliferation is not merely a paraneoplastic phenomenon of questionable importance but leads to the suppression of host immunity and promotion of tumor angiogenesis, both of which play an integral part in tumorigenesis and metastasis. Therefore, cancer-associated myeloproliferation represents a novel therapeutic target in cancer that, decades after its recognition, is only now being translated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.